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79 years estimated to be living with diabetes,1 and this
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Background: Pen needles (PNs) are essential for
insulin injections using pen devices. PN characteristics
affect patients’ injection experience.
Objective: The goal of this study was to evaluate the
impact of a new extra-thin wall (XTW) PN versus usual
PNs on overall patient preference, ease of injection, per-
ceived time to complete the full dose, thumb button force
to deliver the injection, and dose delivery conﬁdence in
individuals with diabetes mellitus (DM). Subjects injected
insulin with the KwikPenTM (Eli Lilly and Company,
Indianapolis, Indiana), SoloSTARs (sanoﬁ-aventis U.S.
LLC, Bridgewater, New Jersey), and FlexPens (Novo
Nordisk A/S, Bagsvaerd, Denmark) insulin pens, and
included some with impaired hand dexterity.
Methods: We ﬁrst performed quantitative testing of
XTW and comparable PNs with the 3 insulin pens for
thumb force, ﬂow rate, and time to deliver medication.
A prospective, randomized, 2-period, open-label, cross-
over trial was then conducted in patients aged 35 to 80
years with type 1 or type 2 DM who injected insulin by
pen for ≥2 months, with at least 1 daily dose ≥10 U.
Patients who used 4- to 8-mm length PNs with 31- to
32-G diameter were randomly assigned to use their
current PN or the same/similar size XTW PN at home
for 1 week and the other PN the second week. They
completed several comparative 150-mm visual analog
scales and direct questions at the end of period 2.
Results: XTW PNs had statistically signiﬁcant better
performance for each studied PN characteristic (thumb
force, ﬂow, and time to deliver medication) for all pens
combined and each individual pen brand (all, P ≤ 0.05).
Of 216 patients randomized to study groups (80, Solo-
STAR; 77, FlexPen; 59, KwikPen), 209 completed both
periods; 198 were evaluable. Baseline characteristics
revealed a mean (SD) age of 60.8 (9.3) years, insulin
pen use duration of 4.3 (4.1) years, and mean total daily
dose of 75.1 (52.3) U (range, 10–420 U). ApproximatelyJuly 201350% of patients were female; 81.5% were white and
14.8% were black; and 89.8% had type 2 DM. Nearly
99% used a single PN: 8 mm, 49.5%; 5 mm, 24.1%; 6
mm, 14.4%; and 4 mm, 12.0%. Patients rated the XTW
PNs (mean [95% CI]) as preferable by a mean of 31.9
mm (27.2–36.6), P o 0.001; XTW PNs required less
thumb force, less time to inject the dose, and were rated
as providing greater conﬁdence in full dose delivery by
28.4 mm (23.7–33.2), 21.7 mm (17.0–26.4), and 24.4
mm (19.7–29.1), respectively; all, P o 0.001. Results
were similar for each of the 3 pens, those with impaired
hand dexterity, and for all users of 4-mm PNs. Skin
leakage and insulin dripping from the needle tip were
rated as less frequent with the XTW PNs (Po 0.05). The
most common adverse events were hypoglycemia in
8.3% and 6.0% of patients using XTW PNs and current
PNs (P ¼ NS), respectively; hyperglycemia occurred in
2.9% and 4.1% (P ¼ NS). None of the adverse events
was serious or considered device related.
Conclusions: XTW PNs were preferred overall, rated
as requiring less time and less thumb force to inject, and
providing greater conﬁdence in completing a full dose
compared with usual PNs in this group of patients with
type 1 or type 2 DM. ClinicalTrials.gov identiﬁer:
NCT01852136 (Clin Ther. 2013;35:923–933)
& 2013 The Authors. Published by Elsevier Inc.
INTRODUCTION
Open access under CC BY-NC-SA license. 923
Clinical Therapeuticsnumber is projected to increase to 4552 million by
2030.2 Of all patients, 490% have type 2 diabetes
mellitus (DM); 30% of all patients use insulin, and
the trend toward injecting with pen devices versus
syringe and vial is increasing.3–5
Since the introduction of insulin pens in the mid-
1980s, insulin pen and pen needle (PN) designs have
both improved to create a better injection experience
for patients, with PNs in particular becoming shorter
and thinner.6–8 To further enhance the injection
process with insulin pens, a new PN with an extra-
thin wall (XTW) cannula has been designed to have
the same outer diameter as regular or thin wall needles
of the same gauge but with a thinner wall, resulting in
a wider inner diameter by 430% (Figure 1).
International Organization for Standardization (ISO)
standard 9626 1991-09-01 provides allowable mini-
mum inner needle diameters for 31-G regular needles
and thin wall needles of 0.114 and 0.125 mm,
respectively, and for 32 G, 0.089 mm, and 0.105
mm.9 Even small changes in internal diameter can lead
to substantial increases in ﬂuid ﬂow and/or reductions
in pressure (eg, thumb button force) to maintain ﬂow,
because these are proportional to the fourth power of
the internal diameter according to Poiseuille's law.10
The XTW needles also incorporate a recently
developed 5-bevel needle tip design.11
We ﬁrst performed quantitative, comparative labo-
ratory testing of both current and new XTW PNs for
thumb force, ﬂow rate, and time to deliver medication.
Second, to determine the impact of the new PN designRegular wall
Thin wall
Extra-thin wall
Figure 1. Illustration of different insulin pen
needle wall thicknesses (not to scale).
924on those injecting insulin with pens, we conducted an
injection experience clinical study in insulin-requiring
patients with DM, comparing the XTW PN with their
usual PN.PATIENTS AND METHODS
Quantitative Testing Method
The objectives of the quantitative testing were to
assess differences in thumb force, ﬂow rate, and time
to deliver medication between similar size, thin wall
PNs, and XTW PNs. Maximum thumb force was
measured by using an Instron Universal Testing
Machine (Instron, Norwood, Massachusetts) by
delivery of 50 U of insulin at a constant volumetric
ﬂow rate of 6 mL/min (equivalent to 10 U/second)
through a given PN attached to an insulin pen, per
ISO standard 11608-3:2000(E).12 Flow rate and
time to deliver were also similarly evaluated by
maintaining a constant thumb force of 4.5 pounds
and by measuring corresponding time required to
dispense the dose. This testing was performed by
dispensing 50 U of insulin and calculating the
portion of this dose delivered at steady force, as
well as corresponding time. All insulin was
dispensed through air into a dose collection disk.
These tests were conducted on the FlexPens (Novo
Nordisk A/S, Bagsvaerd, Denmark), SoloSTARs
(sanoﬁ-aventis U.S. LLC, Bridgewater, New Jersey),
and KwikPenTM (Eli Lilly and Company,
Indianapolis, Indiana). XTW PN sizes of 32 G  4
mm, 31 G  5 mm, and 31 G  8 mm were
compared with 3 groups of commercially available
PNs from various manufacturers, respectively: (1) 32
G  4 to 8 mm; (2) 31 G  4.5 to 6 mm; and (3) 31
G  8 mm. Three lots of each comparator PN (with
the exception of 1 for which only 1 lot was
available) were compared with 2 lots of each XTW
PN size. All testing was completed by a trained
technician.Quantitative Testing Statistical Methods
and Criteria
To provide 90% power to detect statistically sig-
niﬁcant differences (P ≤ 0.05) between XTW PNs and
current PNs, sample sizes of 15 to 45 PNs were
selected. This was determined with the use of 1-way
ANOVA and Dunnett’s multiple comparisons13 and
previously observed estimates of thumb forceVolume 35 Number 7
–75 mm
Week 1
pen needle
greatly preferred
Week 2
pen needle
greatly preferred
No
difference
0 mm 75 mm
Figure 2. A horizontal 150-mm length visual
analog scale (not to scale) of prefer-
ences. Vertical line placed through the
scale line indicates preference rating.
A line to the left of the center mark
indicates that the pen needle used in
study period 1 was preferred more
than the pen needle used in study
period 2. A line to the right of the
center mark indicates that the pen
needle used in study period 2 was
preferred.
R. Aronson et al.variability with 32-G PNs (range, 0.2–2.0 pounds)
and other PN gauges (range, 0.5–7.0 pounds).
Clinical Study Method
This prospective, multicenter, randomized,
open-label, 2-period, crossover study was designed
to assess a number of patient perceptions and
ratings regarding insulin injections between pa-
tients’ usual PN and the corresponding XTW
needle, while maintaining usual insulin doses given
with the same insulin pen and injection routine.
The protocol incorporated 2 in-home usage periods
each lasting 1 week. The study took place
between October and December 2012 at 5 sites (1
in Canada and 4 in the United States) and was
performed in accordance with the Declaration of
Helsinki14 and the Good Clinical Practice
Guideline15 and the International Standards
Organization.16 The protocol was approved by
the Medical Devices Bureau Health Canada and
Schulman Associates IRB, Inc. Before human use,
the experimental device underwent all required
regulatory biocompatibility testing.
Eligible patients were between 35 and 80 years of
age, had type 1 or type 2 DM, self-injected insulin
with a pen device at least once daily for ≥2 months
before enrollment, with at least 1 dose 410 U, using
either a SoloSTAR, KwikPen, or FlexPen. PNs used
by patients had lengths of 4, 5, 6, or 8 mm and a
diameter of 31 or 32 G. Exclusion criteria included
current or history of a medical condition that would
contraindicate treatment with study products or
other conditions, which, in the opinion of the inves-
tigator, would place the patient at risk or have the
potential to confound interpretation of the study
results (eg, recent history of ketoacidosis, hypoglyce-
mic unawareness); a history of intravenous drug use;
or pregnancy.
At the ﬁrst visit, patients gave written informed
consent; provided a sample of their current PN,
medical history, demographic information (including
self-assessment for hand strength or dexterity issues);
and completed the Duruöz Hand Index assessment
tool, which in patients with DM, shows good corre-
lation with a hand function index (Po 0.001 and r ¼
0.586).17 This tool contains 18 questions regarding
ability to perform various activities of daily living, and
their responses were scored on a 6-point Likert scale
(0 ¼ yes, without difﬁculty to 5 ¼ impossible).July 2013Patients were then randomly assigned to use either
the experimental PN or their usual PN for 1 week at
home. Each investigational site was provided with a
computer-generated PN randomization schedule. All
patients were provided with a diary to record any
adverse events (AEs) and device malfunctions. Patients
who used 41 brand of pens evaluated each but were
assigned to a pen category based on the most
frequently used pen. Although patients were aware
of the investigational PN usage (indicated on the pen
needle label), no descriptive information was provided
related to needle design or characteristics. Patients
using the relatively new BD (Becton, Dickinson and
Company; Franklin Lakes, New Jersey) 5-bevel PNs
were standardized to equivalent 3-bevel BD PNs as
their reference (current) PN because the XTW PNs are
5-bevel. After the ﬁrst week, patients were crossed-
over to the other study PN. The primary objective was
to determine whether the patients prefer the XTW
PNs over their usual PNs (all patients), using a
comparative 150-mm visual analog scale (VAS)
(Figure 2).
Secondary objectives also used VAS scales and
assessed thumb force to deliver insulin, conﬁdence in
delivering a full dose of insulin, and perceived time to
deliver insulin (all patients, all pens). Subanalyses of
the aforementioned objectives (except conﬁdence)
according to each speciﬁc pen brand were also
secondary objectives. In tertiary objectives, patients925
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Clinical Therapeuticsusing the BD Nanos (Becton, Dickinson and Com-
pany) 4 mm  32 G PN (all pens) compared it with
the XTW version for preference. Differences in the
occurrence of insulin leakage from the skin or needle
and of bruising/bleeding were reported by patients at
the ﬁnal visit. Similar outcomes were also evaluated
in a prespeciﬁed analysis among the subset of patients
having self-reported manual dexterity challenges.
Finally, correlational analyses were conducted be-
tween the Duruöz Hand Index scores and the afore-
mentioned identiﬁed outcomes.
Clinical Study Statistical Methods and Criteria
A linear mixed effect model (with Subjects as
random effects, Period and VAS as ﬁxed effects)
was used for the analysis of responses recorded on
VAS. The signs of the measured VAS scores were
adjusted depending on which PN was used in period
1, so that the scores would directly represent relative
differences of investigational PN – current PN, with
positive readings corresponding to better investiga-
tional PN performance. Least-squares means for each
VAS were calculated along with simultaneous 95%
CIs for all VAS responses. The primary preference
objective, secondary objectives (thumb force, conﬁ-
dence in full dose delivery, and injection time), and
the tertiary objectives (pain, ease of insertion, and
convenience) (all patients) were considered statisti-
cally signiﬁcant if the entire 95% CI for the mean
VAS score was either positive (XTW preferred) or
negative (current PN preferred).
A ﬁxed Pen Brand effect was added to the model
for the analysis of the secondary objectives per pen
brand, and the same CI criterion was used per pen
brand. Similar analyses were performed for the
patients using the Nano 4-mm PN and for the
patients with self-identiﬁed manual dexterity chal-
lenges; signiﬁcance of the correlations between the
Duruöz Hand Index score and the VAS for identiﬁed
outcomes was assessed by using the P value of the
Duruöz Hand Index score in the model. For insulin
leakage, insulin dripping, and bleeding/bruising, the
difference in the proportion of patients selecting the
XTW PN over their current PN was calculated, with
95% CIs adjusted for the percentage of “both were
the same” and “did not occur” responses.
A sample size of 180 patients (all patients pooled)
was determined to give 95% power to detect an
average relative difference of 10 mm on the VAS926 Volume 35 Number 7
R. Aronson et al.(assuming an SD of 37 mm for relative VAS scores,
based on results from a previous study and a t test
procedure).11 In addition, a sample size of 180
patients was sufﬁcient to provide 90% power to
detect a signiﬁcant preference for XTW PNs (based
on a Monte-Carlo simulation). A sample size of 60
patients for each pen brand with the same SD givesVisit 1: Patients enrolled, randomized to tr
and met inclusion/exclusion criteri
n = 216
Patients screened
N = 223
n = 
Patients random
pen ne
(KwikPen = 29
SoloSTA
n = 108
Patients randomized to
investigational pen needle 1st
(KwikPen = 30, FlexPen = 39,
SoloSTAR = 39)
n = 106
Visit 2: Patients continued
cross-over to current pen needle
(KwikPen = 29, FlexPen = 38,
SoloSTAR = 39)
Visit 3: Patients completed, n = 209
KwikPen = 57
FlexPen = 74
SoloSTAR = 78
Patients used in analysis, n = 198
KwikPen = 54
FlexPen = 71
SoloSTAR = 73
Lilly KwikPen*
n = 59
Novo Nordisk FlexPen†
n = 77
n = 
Visit 2: Patients co
to investigation
(KwikPen = 28
SoloSTA
Figure 3. Study patient flow. AE ¼ adverse event.
Indianapolis, Indiana). †Trademark: FlexPens
mark: SoloSTARs (sanofi-aventis U.S. LLC, B
July 201390% power to detect an average relative difference of
16 mm on the VAS. To obtain at least 180 evaluable
patients, target enrollment was 210 patients. The
enrollment of 30 patients over the target was consid-
ered to be sufﬁcient because the attrition rate was
anticipated to be low due to the short study duration,
without any changes to patients’ usual insulin therapy.eatment,
a
108
ized to current
edle 1st
, FlexPen = 38,
R = 41)
Sanofi-Aventis SoloSTAR‡
n = 80
105
ntinued cross-over
al pen needle*
, FlexPen = 36,
R = 41)
7 - Not enrolled
6 – failed inclusion/exclusion criteria
1 – enrollment in pen group completed
11 - Not used in patient ratings analysis
10 – incorrect pen needle dispensed
1 – protocol violation (inappropriate inclusion)
2 - Discontinued
1 – protocol violation (wrong pen needle)
1 – noncompliance (changed insulin regimen)
5 - Discontinued
2 – AE/concurrent illness
3 – other (lack of transportation, unable
to continue self-injecting, unable to return
for next visit)
*Trademark: KwikPenTM (Eli Lilly and Company,
(Novo Nordisk A/S, Bagsvaerd, Denmark). ‡Trade-
ridgewater, New Jersey).
927
Clinical TherapeuticsRESULTS
Quantitative Testing
XTW PNs had statistically signiﬁcant better per-
formance for each studied PN characteristic (thumb
force, ﬂow, and time to dispense medication) for all
pens combined and each individual pen brand (all, P ≤
0.05) (Table I). Mean maximum thumb force was
signiﬁcantly lower with the XTW PN at 2.7 pounds
for the 32-G  4-mm PN versus the comparable 32-G
needles at 5.8 to 8.8 pounds; 31-G  5-mm XTW PN,
2.2 pounds versus 3.1 to 6.0 pounds; and 31 G  8
mm XTW PN, 2.3 pounds versus 4.7 to 6.1 pounds.
Time required to dispense 50 U was signiﬁcantly less
with the XTW PNs for both 32- and 31-G PNs: 2.9
seconds with the 32-G XTW versus 6.1 to 8.7 seconds
with the other 32-G needles; 2.2 seconds with the 31-
G  5-mm XTW whereas the comparable 5- to 6-mm
PNs required 3.5 to 6.3 seconds. The time for the 31-
G  8-mm XTW PN was 2.3 seconds, with the
remaining 8-mm PNs ranging from 4.9 to 6.1 seconds.
In terms of percent difference, compared with their
regular and thin wall comparator PNs, the 31- and
32-G XTW PNs reduced the average thumb force to
deliver medication by 47% to 62%, increased ﬂow
rate by 108% to 149%, and reduced the time to
deliver medication by 52% to 60% (all, p o 0.05)
(Table I). Supplemental Figure 1 graphically presents
each comparator PN in the online version at http://dx.
doi.org/10.1016/j.clinthera.2013.05.020. Earlier quan-
titative tests as per ISO Standard 9626 for cannula
bending and breakage demonstrated no statistical
differences between BD’s current thin wall and the
XTW PNs (data not shown).9
Clinical Study
A total of 223 patients were screened, with 216
enrolled and randomized to treatment group (80, 77,
and 59 classiﬁed as SoloSTAR, FlexPen, and KwikPen
pen users, respectively); 209 completed the study
(attrition 3.2%), and 198 provided evaluable data
(attrition 8.3%) (Figure 3). Baseline characteristics
revealed a mean (SD) age of 60.8 (9.3) years, insulin
pen use duration of 4.3 (4.1) years, and mean total
daily dose of 75.1 (52.3) U (range, 10–420 U). Nearly
99% used only 1 type of PN, with the 8-mm length
the most frequent choice (49.5%); usage of the 4-mm
PN was 12%. There were some signiﬁcant differences
between the 3 pen groups, including: the proportion
of patients with type 2 DM was lower in the KwikPen928versus the SoloSTAR group (P ¼ 0.002); and com-
pared with the other 2 pens, SoloSTAR users had
fewer years with diabetes (P ¼ 0.002), shorter dura-
tion of insulin treatment (P o 0.001) and of pen use
(P o 0.001), and fewer daily doses (P o 0.001)
(Table II). Currently used PNs were 72% BD, 17%
Novo Nordisk, and 10% other manufacturers. Forty-
six (21%) patients self-reported hand dexterity issues,
with a mean (SD) Duruöz Hand Index score of 0.52
(0.52) compared with those without self-reported
hand challenges, who had a score of 0.03 (0.13).
For the primary objective of overall preference,
patients preferred the XTW PNs compared with their
usual PNs, with a mean VAS score difference of 31.9
mm (95% CI, 27.2–36.6; P o 0.001). Signiﬁcant
differences favoring the XTW PNs were seen for the
secondary objectives, including perceived thumb force,
time to inject the dose, and conﬁdence that the full
dose was delivered by 28.4 mm (95% CI, 23.7–33.2),
21.7 mm (95% CI, 17.0–26.4), and 24.4 mm (95%
CI, 19.7–29.1), respectively; all, P o 0.001)
(Figure 4). More details are given in Supplemental
Table I in the online version at http://dx.doi.org/
10.1016/j.clinthera.2013.05.020. Similar statistically
signiﬁcant ﬁndings for preference, thumb force, and
conﬁdence were demonstrated in secondary analyses
for each of the 3 insulin pens (all, P o 0.001). In the
subset of 4-mm  32-G PN users (n ¼ 21), the XTW
PN was also preferred over the current 4-mm product
by 35.1 mm (95% CI, 20.6–49.6; P o 0.001), with
62% preferring the XTW versus 0% for the thin wall
version. The linear mixed effect model indicated no
signiﬁcant impact whether XTW PNs were tested in
the ﬁrst or second study periods.
Distribution of VAS responses favoring XTW PNs
or current PNs for speciﬁed characteristics, excluding
those indicating no difference, were as follows: overall
preference, 68.2% versus 11.6%, respectively; less
thumb force, 60.6% versus 7.1%; more conﬁdence of
full dose delivery, 51.5% versus 9.1%; reduced injec-
tion time, 48.5% versus 4.5%; less pain, 64.1% versus
9.6%; insertion ease, 63.6% versus 6.1%; and more
convenient, 36.4% versus 4% (Figure 5). Results were
similar in patients with self-reported hand dexterity/
strength challenges (as presented in Supplemental Table
II and Supplemental Figure 2 in the online version at
doi:10.1016/j.clinthera.2013.05.020). There were no
signiﬁcant correlations between Duruöz Hand Index
and the VAS scores (all, P 4 0.4).Volume 35 Number 7
Table II. Baseline patient characteristics.
Characteristic
Total
(N ¼ 216)
SoloSTARsa
(n ¼ 80)
FlexPensb
(n ¼ 77)
KwikPenTMc
(n ¼ 59)
Age, y
Mean (SD) 60.8 (9.3) 60.3 (9.3) 61.8 (9.3) 60.1 (9.4)
Range 35–80 37–78 35–78 38–80
Sex
Female 109 (50.5%) 45 (56.2%) 37 (48.1%) 27 (45.8%)
Diabetes typed
Type 1 22 (10.2%) 2 (2.5%) 8 (10.4%) 12 (20.3%)
Type 2 194 (89.8%) 78 (97.5%) 69 (89.6%) 47 (79.7%)
Race, no. (%)
White 176 (81.5%) 66 (82.5%) 66 (85.7%) 44 (74.6%)
Black 32 (14.8%) 13 (16.2%) 9 (11.7%) 10 (16.9%)
Other 8 (3.7%) 1 (1.3%) 2 (2.6%) 5 (8.5%)
Years with diabetes
Mean (SD) 16.2 (9.7) 13.3 (7.5) 17.0 (9.9) 19.0 (11.2)
Range 0.2–49 0.2–36.2 0.3–41 1.5–49
Years receiving insuline
Mean (SD) 8.7 (9.3) 5.4 (5.0) 9.0 (8.4) 12.6 (12.9)
Range 0.1–49 0.1–20.8 0.3–41 0.4–49
Years using insulin penf
Mean (SD) 4.3 (4.1) 3 (2.9) 4.5 (4.3) 5.9 (4.7)
Range 0.1–30 0.1–15 0.3–30 0.4–20
Insulin dosage per injection
Mean (SD) 26.2 (21.2) 27.5 (22.8) 26.9 (21.4) 24.4 (19.6)
Range 1–120 2–114 1–120 5–110
Total daily insulin dosageg
Mean (SD) 75.1 (52.3) 56.5 (37.3) 83.2 (64.3) 90.0 (45.4)
Range 10–420 10–224 10–420 10–210
Doses per day, no. (%)h
Single 56 (25.9%) 41 (51.2%) 13 (16.9%) 2 (3.4%)
41 160 (74.1%) 39 (48.8%) 64 (83.1%) 57 (96.6%)
Primary pen needle length, mm
8 107 (49.5%) 41 (51.2%) 42 (54.5%) 24 (40.7%)
5 52 (24.1%) 22 (27.5%) 19 (24.7%) 11 (18.6%)
6 31 (14.4%) 10 (12.5%) 11 (14.3%) 10 (16.9%)
4 26 (12.0%) 7 (8.8%) 5 (6.5%) 14 (23.7%)
Primary pen needle gauge
31 168 (77.8%) 66 (82.5%) 65 (84.4%) 37 (62.7%)
32 48 (22.2%) 14 (17.5%) 12 (15.6%) 22 (37.3%)
Nonsignificant differences for remaining characteristics.
aTrademark: sanofi-aventis U.S. LLC, Bridgewater, New Jersey.
bTrademark: Novo Nordisk A/S, Bagsvaerd, Denmark.
cTrademark: Eli Lilly and Company, Indianapolis, Indiana.
dKwikPen versus SoloSTAR fewer type 2, P ¼ 0.002.
SoloSTAR fewer years diagnosed with diabetes than other 2 pens, P ¼ 0.002.
eSoloSTAR fewer years receiving insulin than other 2 pens, P o 0.001.
fSoloSTAR fewer years using pen than other 2 pens, P o 0.001.
gSoloSTAR lower total daily dose than other 2 pens, P o 0.001.
hSoloSTAR fewer number of daily injections than other 2 pens, and FlexPen fewer number of daily injections than KwikPen,
both P o 0.001.
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Thumb force
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Injection time
Pain
Insertion ease
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Figure 4. Ninety-five percent CIs for average visual analog scale (VAS) scores. All pens and pen needles
(positive readings indicate a preference for extra-thin wall [XTW] pen needles) (N ¼ 198). The signs
of the measured VAS scores were adjusted depending on which pen needles was used in study
period 1, so that the scores would directly represent the relative differences of investigational pen
needle – current pen needle.
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reporting leakage from the skin, dripping from the
needle, and bruising/bleeding from the injection site
indicate signiﬁcantly fewer events with XTW PNs
versus current PNs (Table III). Reports of clinically
relevant problems with PNs (eg, bent needle) were
infrequent and similar between current (0.4%) and
XTW (0.6%) PNs.
Ninety-nine AEs were reported by 44 patients; 2
AEs were serious but not considered related to the
product, with both occurring in the ﬁrst study period.
One was infectious pancolitis in a patient using an
XTW PN, and the other was a hip fracture in a patient
using the usual PN. Three AEs were rated as probably
product related: bleeding at injection site, all in
patients using their usual PN. AEs were reported by
26 patients (12.7%) when using the XTW PN, and 21
patients (9.6%) with the usual PN (P ¼ NS). The most
frequent AEs were hypoglycemia (8.3% of patients
using the XTW PN, 6% with the usual PN) and
hyperglycemia (2.9%, XTW PN; 4.1%, usual PN),
both P ¼ NS. More details regarding AEs are given
in Supplemental Table III in the online version at
http://dx.doi.org/10.1016/j.clinthera.2013.05.020.
DISCUSSION
The force (and time) required to deliver medication
by pen injection devices are important considera-
tions for patients and health care professionals or
other caregivers who administer injections.18 In the
current report, we have presented both quantitative
testing of PN characteristics and a clinical study of
patient-reported comparative ratings in 3 different
insulin pens during home use, varying only the
internal open diameter of otherwise identical (orTable III. Distribution of responses for the less leaking, d
given as n (%) unless otherwise indicated.
Variable No Occurrence
Extra-Thin Wall
Pen Needle No D
Less leakage 74 (37.4) 70 (35.4) 31
Less insulin
dripping
62 (31.3) 75 (37.9) 45
Less bruising/
bleeding
73 (36.9) 72 (36.4) 35
July 2013nearly-so) PNs. The quantitative testing demon-
strated reduced thumb force, increased ﬂow rate,
and less time to deliver insulin with the new XTW
PN compared with multiple currently available PNs.
These ﬁndings are consistent with the physical
properties of the XTW needle: the increase in
internal cannula diameter of 430% increases in-
sulin ﬂow at a constant thumb button force (leading
to less time to dispense a dose), or reduces thumb
force to administer a given dose volume at a set
speed, per Poiseuille's law.10
The clinical study showed that these PN perform-
ance improvements were consistently perceived by
patients. During 1 week of home use, all patients
reported a statistically signiﬁcant overall preference
for the XTW PN compared with their current PN by
nearly 6-fold, as did the users of each of the KwikPen,
FlexPen, and SoloSTAR pens. Key secondary meas-
ures were similarly rated favoring the XTW PN by all
patients: less thumb force, reduced time to inject the
dose, and conﬁdence that the complete dose had been
delivered. Users of each type of insulin pen rated the
XTW PN as requiring less thumb force and providing
greater dosing conﬁdence.
The force needed to deliver medication by pen
devices may be especially important to those with
hand strength or dexterity issues, such as the elderly
or those with neuropathy or arthritis. We included an
objective rating of manual dexterity17 in our study
and prospectively analyzed results in the subset of
patients with a degree of impaired dexterity (self-
reported). Importantly, the patient preference beneﬁts
identiﬁed were consistent among both patients with
dexterity challenges and those without. We also
evaluated outcomes in the subset of patients usingripping, and bruising/bleeding (N ¼ 198). Values are
ifference
Current Pen
Needle
Extra-Thin Wall
– Current (%) 95% CI
(15.7) 23 (11.6) 23.7 12.4–34.2
(22.7) 16 (8.1) 29.8 18.9–39.6
(17.7) 18 (9.1) 27.3 16.3–37.3
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Clinical Therapeuticsthe very small 4-mm  32-G PN, and these ﬁndings
were again consistent with the larger cohort.
Signiﬁcant improvements with the XTW PN were
found in relative pain, ease of insertion, and conven-
ience, as well as leakage from the skin or dribbling
from the needle tip and bruising or bleeding at
injection sites. Previous studies have consistently
demonstrated equal glycemic control, less pain, and
greater patient preference for thinner-diameter and/or
shorter-length needles.8,19–22 Nearly all studies have
found no increase in leakage/backﬂow from the skin,
with 1 exception (of limited clinical signiﬁcance),20
and some report less patient anxiety/fear.8,22 A pre-
vious open-label crossover study in patients using
regular wall versus thin wall PNs reported that
patients preferred the thin wall needle overall, found
it required less effort, and allowed faster injections.23
Thus, our ﬁndings conﬁrm and extend these previous
studies and illustrate that enlarging internal needle
diameter improves the injection experience for pen
users. Although not studied quantitatively, patient
reports of less insulin leakage from the skin (3 times
less frequent with XTW) and less dripping from the
needle tip (4.6 times less frequent with XTW) may
signal that more of the dose was appropriately
dispensed, possibly contributing to the ratings of
greater conﬁdence that the full dose was delivered.
However, these observations are subjective, and the
effect of XTW PNs on dose accuracy and precision
requires additional study. The impact of ﬁndings like
these on glycemic control and patient health outcomes
remains to be determined.
Limitations of the study include its lack of patients
aged o35 years, its short duration, and lack of
measurement of blood glucose levels. Based on several
previous studies showing noninferior or equivalent
blood glucose control between PNs of different length
and/or gauge,8,19–22 the expectation was that glycemic
control would not differ in this short-term trial. We
elected to recruit an older group of patients to increase
the probability of enrolling those with hand strength
and dexterity challenges. The degree of impaired
manual dexterity according to the Duruöz Hand
Index in that subgroup was mild; however, the
subgroup analyses were prespeciﬁed. Although the
study was open label, patients were provided very
limited information about the investigational needle.
Speciﬁcally, they were not given any information
suggesting any changed physical characteristics of932the investigational PN, and given the consistent
external diameter visible to each patient, there would
be limited bias to favor the investigational PN.CONCLUSIONS
The ETW PNs improved ﬂow and pressure, and
provided an easier-to-use, more convenient injection
experience, with signiﬁcantly better overall patient
preference, lower thumb button force, reduced time
to inject, and greater patient conﬁdence in completing
the full injection in this group of patients with type 1
and 2 DM. Pain was reduced, and reported leakage
was less with the new needle. These ﬁndings were
consistent among users of the KwikPen, SoloSTAR,
and FlexPen insulin pens and in those with mild hand
dexterity issues.ACKNOWLEDGMENTS
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Figure 1. Quantitative testing results: average percent decrease or increase (range) with extra-thin wall (XTW)
pen needles compared with similar gauge (31 G and 32 G) thin wall and regular wall pen needles for
thumb force, flow rate and time to deliver medication with the KwikPenTM (Eli Lilly and Company,
Indianapolis, Indiana), FlexPens (Novo Nordisk A/S, Bagsvaerd, Denmark), and SoloSTARs (sanofi-
aventis U.S. LLC, Bridgewater, New Jersey) insulin pens. The horizontal line represents the mean
difference between XTW and comparator pen needles for all pen needles in a specific category (pen,
needle gauge); the black circle represents the mean for the difference between XTW and a specific
comparator pen needle; and the vertical line through the circle represents the percent range difference
between XTW and a specific comparator pen needle. All differences compared with the XTW pen
needles were significant (P o 0.05).
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Figure 2. Distribution of preference for extra-thin wall and current pen needles with patients who self-
reported hand dexterity/strength challenges, N ¼ 41.
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Table I. Visual analog scale summary statistics (in millimeters), N ¼ 198.
Variable
Least-Squares
Mean 95% CI Median SD Minimum Maximum P
XTW PN
Preferred
Overall preference 31.9 27.2–36.6 37.5 38.4 –75 75 o0.001 True
Thumb force 28.4 23.7–33.2 22.5 34.6 –75 75 o0.001 True
Full dose delivery
confidence
24.4 19.7–29.1 7.5 36 –75 75 o0.001 True
Injection time 21.7 17–26.4 0 30.8 –60 75 o0.001 True
Pain 30 25.3–34.8 30 37.4 –75 75 o0.001 True
Insertion 31.8 27.1–36.5 33.8 33.7 –67.5 75 o0.001 True
Convenient use 16.9 12.2–21.6 0 28.7 –45 75 o0.001 True
XTW ¼ extra-thin wall; PN ¼ pen needle.
Positive scores indicate better performance for the XTW PN. A completely positive 95% CI for the visual analog scale score
indicates that the XTW PN was rated as statistically significantly better than the patient’s current PN.
Table II. Self-reported manual dexterity challenges: distribution of positive, neutral, and negative scores on
the visual analog scale, N ¼ 41.
Variable
Preference for
ETW (%)
No
Difference
(%)
Preference for Current
PN (%)
XTW PN – Current
PN (%) 95% CI
Overall preference 70.7 17.1 12.2 58.5 21.9–80
Thumb force 61 29.3 9.8 51.2 15.6–74.6
Full dose delivery
confidence
58.5 31.7 9.8 48.8 13.5–72.6
Injection time 48.8 41.5 9.8 39.0 5.5–64
Pain 65.9 22.0 12.0 53.7 16.4–77.5
Insertion force 70.7 17.1 12.2 58.5 21.9–80
Convenient to use 34.1 63.4 2.4 31.7 5.5–53.6
XTW ¼ extra-thin wall; PN ¼ pen needle.
Positive scores indicate preference for the XTW PN. The 95% CIs for the difference in percentage of patients with a preference
for the XTW PN and their current PN indicate a significantly higher percentage of patients who prefer the XTW PN.
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Table III. Adverse events (AEs) and relationship to pen needle used; total reported events ¼ 99.
Pen Needle Used
No. of Patients
Who Reported AEs* Probably Possibly Unlikely Not Related Total
Extra-thin wall 26 0 0 2 46 48
Usual 21 3† 0 1 31 35
Unknown‡ 13 0 1§ 0 15 16
*NS, P ¼ 0.40.
†Bleeding at injection site.
‡Date missing or AE occurred on day of visit 2, and it is unknown whether AEs occurred in period 1 or period 2.
§Burning from injection.
R. Aronson et al.
